Chemerin rs17173608 Gene Polymorphism is not Associated with Type 2 Diabetes Mellitus: a Cross-sectional Study

Open access


Background: Previous studies have shown that chemerin has important roles in the development of obesity, insulin resistance, metabolic syndrome, polycystic ovary syndrome (PCOS) and T2DM. The main goal of our study was to investigate the role of Chemerin rs17173608 gene polymorphism in T2DM (type 2 diabetes mellitus).

Materials and methods: 100 patients with T2DM and 50 healthy volunteers were included in the present study. DNA isolation from blood samples was performed with K1820-02 DNA Mini Kit. Chemerin gene polymorphism was detected by Tetra- Amplification Refractory mutation system polymerase chain reaction (T-ARMS-PCR). At the end of T-ARMS-PCR, samples were run using gel electrophoresis. Some samples were validated by sequence analysis.

Results: In the genotype analysis, 18.0% of patients had TT genotype and 81.0% of TG genotype was detected. GG genotype was not detected in any patient. Genotype of 1 patient was unidentified. Genotype distribution of healthy control group was 12.0% TT genotype and 88.0% TG genotype. Similar to the T2DM group, the GG genotype was not detected in the control group. There was no statistically significant difference between T2DM group and healthy control group for TG and TT genotypes.

Conclusion: To our knowledge, chemerin rs17173608 gene polymorphism has been investigated in T2DM for the first time herein. In the present study, the TT genotype ratios were higher in the T2DM subjects than in healthy subjects. G allele frequency in the T2DM group was lower than that in the control group. However, there was no statistically significant difference between the groups.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Bongaerts BW Mussig K Wens J et al. Effectiveness of chronic care models for the management of type 2 diabetes mellitus in Europe: a systematic review and meta-analysis. BMJ Open 2017;7(3):e013076.

  • 2. Rehman K Akash MSH. Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they ınterlinked? J Cell Biochem 2017;118(11):3577-85.

  • 3. Vegiopoulos A Rohm M Herzig S. Adipose tissue: between the extremes. EMBO J 2017;14;36(14): 1999-2017.

  • 4. Zimny S Pohl R Rein-Fischboeck L et al. Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic stellate cells and is positively associated with characteristics of non-alcoholic steatohepatitis in mice and men. Exp Mol Pathol 2017;103(1):1-8.

  • 5. Ozcan E Saygun NI Ilikci R et al. Evaluation of chemerin and its receptors ChemR23 and CCRL2 in gingival tissues with healthy and periodontitis. Odontology 2017;21(4):1113-21.

  • 6. Wan M Godson C Guiry PJ et al. Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. FASEB J 2011;25(5):1697-705.

  • 7. Cash JL Hart R Russ A et al. Synthetic chemerinderived peptides suppress inflammation through ChemR23. J Exp Med 2008;205(4):767-75.

  • 8. Hashemi M Rezaei H Eskandari-Nasab E et al. Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome a preliminary report. Gene 2012;510(2):113-7.

  • 9. De Palma G Castellano G Del Prete A et al. The possible role of ChemR23/Chemrin axis in the recruitment of dendritic cells in lupus nephritis. Kidney Int 2011;79(11):1228-35.

  • 10. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008;79(8S):1527-34.

  • 11. Gimble JM. Adipose tissue-derived therapeutics. Expert Opin Biol Ther 2003;3:705-13.

  • 12. Trayhurn P Bing C Wood IS. Adipose tissue and adipokines - energy regulation from the human perspective. J Nutr 2006;136(7):1935S-9S.

  • 13. Goralski KB McCarthy TC Hanniman EA et al. Chemerin a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282(38):28175-88.

  • 14. Lago F Dieguez C Gómez-Reino J et al. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007;18(3):313-25.

  • 15. Ouwens DM Bekaert M Lapauw B et al. Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Arch Physiol Biochem 2012;118(3):135-8.

  • 16. Parolini S Santoro A Marcenaro E et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007;109(9):3625-32.

  • 17. Takahashi M Takahashi Y Takahashi K et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008;582(5):573-8.

  • 18. Du X-Y Zabel BA Myles T et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor) and platelets. J Biol Chem 2009;284(2):751-8.

  • 19. Albanesi C Scarponi C Pallotta S et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 2009;206(1):249-58.

  • 20. Dranse HJ Muruganandan S Sinal CJ. Investigating novel mechanisms of chemerin signalling in mature adipocytes. The FASEB Journal 2013;27(1 Supplement): 669.1.

  • 21. Mehanna ET Mesbah NM Ghattas MH et al. Association of chemerin Rs17173608 and vaspin Rs2236242 gene polymorphisms with metabolic syndrome in Egyptian women. Endocrine research 2016;41(1):43-8.

  • 22. Weigert J Obermeier F Neumeier M et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis 2010;16(4):630-7.

  • 23. Tomalka-Kochanowska J Baranowska B Wolinska-Witort E et al. Plasma chemerin levels in patients with multiple sclerosis. Neuro Endocrinol Lett 2014;35(3):218-23.

  • 24. Khaled Y Rashed L. Serum chemerin levels and chemerin rs17173608 genotypes in the susceptibility of diabetic nephropathy in Egyptian diabetic patients. Egypt J Obes Diabetes Endocrinol 2016;2(1):18-22.

Journal information
Impact Factor

CiteScore 2018: 0.587

SCImago Journal Rank (SJR) 2018: 0.311

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 118 118 9
PDF Downloads 106 106 3